Skip to main content

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma.

Publication ,  Journal Article
Sivaraj, D; Green, MM; Kang, Y; Long, GD; Rizzieri, DA; Li, Z; Garrett, AH; McIntyre, JL; Chao, NJ; Gasparetto, C
Published in: Blood Cancer J
July 31, 2018

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Blood Cancer J

DOI

EISSN

2044-5385

Publication Date

July 31, 2018

Volume

8

Issue

8

Start / End Page

71

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Thalidomide
  • Retreatment
  • Recurrence
  • Multiple Myeloma
  • Middle Aged
  • Male
  • Humans
  • Female
  • Drug Resistance, Neoplasm
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sivaraj, D., Green, M. M., Kang, Y., Long, G. D., Rizzieri, D. A., Li, Z., … Gasparetto, C. (2018). Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma. Blood Cancer J, 8(8), 71. https://doi.org/10.1038/s41408-018-0104-5
Sivaraj, Dharshan, Michael M. Green, Yubin Kang, Gwynn D. Long, David A. Rizzieri, Zhiguo Li, Anderson H. Garrett, Jackie L. McIntyre, Nelson J. Chao, and Cristina Gasparetto. “Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma.Blood Cancer J 8, no. 8 (July 31, 2018): 71. https://doi.org/10.1038/s41408-018-0104-5.
Sivaraj D, Green MM, Kang Y, Long GD, Rizzieri DA, Li Z, et al. Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma. Blood Cancer J. 2018 Jul 31;8(8):71.
Sivaraj, Dharshan, et al. “Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma.Blood Cancer J, vol. 8, no. 8, July 2018, p. 71. Pubmed, doi:10.1038/s41408-018-0104-5.
Sivaraj D, Green MM, Kang Y, Long GD, Rizzieri DA, Li Z, Garrett AH, McIntyre JL, Chao NJ, Gasparetto C. Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma. Blood Cancer J. 2018 Jul 31;8(8):71.

Published In

Blood Cancer J

DOI

EISSN

2044-5385

Publication Date

July 31, 2018

Volume

8

Issue

8

Start / End Page

71

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Thalidomide
  • Retreatment
  • Recurrence
  • Multiple Myeloma
  • Middle Aged
  • Male
  • Humans
  • Female
  • Drug Resistance, Neoplasm